MHRA-100472-PIP01-22

Key Facts

Active Substance
Active Substance:
  • Tarlatamab
Invented Name
Not yet available
PIP Number MHRA-100472-PIP01-22
Pharmaceutical form(s)
Pharmaceutical form(s):
  • All pharmaceutical forms.
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
  • Treatment of small cell lung cancer (SCLC)
  • Treatment of prostate malignant neoplasms.
Route(s) of administration
Route(s) of administration:
  • All routes of administration.
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Tarlatamab.pdf
Published Date 02/02/2023